Cabozanib contains cabozantinib, a targeted oral cancer therapy used to treat certain advanced or metastatic cancers. It belongs to a group of medicines known as tyrosine kinase inhibitors, which are designed to interfere with specific pathways that support tumor growth, blood supply, and survival.

This medication is especially valuable in cancers that are difficult to treat, such as renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. Its broad activity against multiple cancer-related kinases makes it a versatile option in oncology.

Mechanism of Action

Cabozantinib targets and blocks the activity of several tyrosine kinases, which are enzymes that help regulate various cell functions including growth and angiogenesis. Key targets of cabozantinib include:

• VEGFR (vascular endothelial growth factor receptor), which controls new blood vessel formation

• MET (hepatocyte growth factor receptor), involved in cell growth and survival

• AXL and RET, which are linked to cancer cell invasion and resistance

By inhibiting these pathways, cabozantinib helps to:

• Reduce the blood supply to tumors

• Prevent cancer cell proliferation and spread

• Slow down tumor growth

  Uses

  Cabozanib is prescribed for the treatment of:

  • Advanced Renal Cell Carcinoma (RCC)
    It is often used after prior treatment with another therapy, or sometimes as a first-line option.

  • Hepatocellular Carcinoma (HCC)
    Used in patients who have previously received sorafenib.

  • Medullary Thyroid Cancer (MTC)
    For cases that are unresectable, locally advanced, or metastatic.

    Adverse Effects

    As with many cancer treatments, cabozantinib can cause side effects. These vary in intensity and should be monitored regularly.

    Common Side Effects

    • Diarrhea

    • Loss of appetite

    • Fatigue

    • Weight loss

    • Nausea

    • High blood pressure

    • Changes in hair color or texture

    • Mouth sores or pain